Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.

CEO

Mr. David P. Perry M.B.A.

Employees

Country

ISIN

US08773T1043

Listings

OTC Link

BTTX

0 Comments

Share your thoughts

FAQ

What is Better Therapeutics stock price today?▼

The current price of BTTX is $0 USD — it has increased by +0% in the past 24 hours. Watch Better Therapeutics stock price performance more closely on the chart.

What is Better Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Better Therapeutics stocks are traded under the ticker BTTX.

What is Better Therapeutics market cap?▼

Today Better Therapeutics has the market capitalization of 4,740.3

What is Better Therapeutics revenue for the last year?▼

Better Therapeutics revenue for the last year amounts to 0 USD.

What is Better Therapeutics net income for the last year?▼

BTTX net income for the last year is -79.52M USD.

How many employees does Better Therapeutics have?▼

As of April 04, 2026, the company has 54 employees.

In which sector is Better Therapeutics located?▼

Better Therapeutics operates in the Health Care sector.

When did Better Therapeutics complete a stock split?▼

Better Therapeutics has not had any recent stock splits.

Where is Better Therapeutics headquartered?▼

Better Therapeutics is headquartered in San Francisco, US.